Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Expert Rev Mol Diagn. 2008;8(4):417-434. The College of American Pathologists (CAP) and ASCO recently organized an expert panel, which conducted a systematic review of the literature and developed ...

significant ... increase in ... time to progression Lapatinib is an oral, reversible, small-molecule dual inhibitor of EGFR and HER2 tyrosine kinases that has demonstrated clinical activity in ...

targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds coupled to an antibody via a linker molecule. The jury in the US District Court for ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

The Spanish team identified the p95HER2 protein, present in a third of HER2 tumors and associated with more aggressive tumors. "We developed a CAR-T against that molecule and found it to be ...

Additionally, in an ER-positive, HER2-negative, PI3Kα-mutant breast ... ENSEM believes this molecule will significantly improve outcomes for patients with PI3Kα mutations, whether in cancer ...